Spero Therapeutics Inc.
Organization details
- Legal name
- Spero Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SPRO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001701108
Board of directors
-
Ankit Mahadevia · Director · CEO and PresidentSince 2023
- Since 2023
-
Esther Rajavelu · Director · See RemarksSince 2026
-
Frank E. Thomas · DirectorSince 2023
-
John C. Pottage Jr. · DirectorSince 2023
-
Kathleen Tregoning · DirectorSince 2023
-
Milind Deshpande · DirectorSince 2023
-
Patrick V.j.j. Vink · DirectorSince 2023
-
Sath Shukla · Director · CEO and PresidentSince 2023
-
Scott Thomas Jackson · DirectorSince 2023
-
William Ho · DirectorSince 2026
Chief executives
Director election results
Annual meeting of June 23, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.2%
-
97.5%
Board connections
4 of this board's directors also sit on 8 other boards. 8 are in the same sector.
-
Agios Pharmaceuticals Inc. Same sectorvia Cynthia Smith
-
Akebia Therapeutics Inc. Same sectorvia Cynthia Smith
-
COMPASS Pathways Plc Same sectorvia Kathleen Tregoning
-
Crescent Biopharma Inc. Same sectorvia Scott Thomas Jackson
-
Larimar Therapeutics Inc. Same sectorvia Frank E. Thomas
-
MacroGenics Inc. Same sectorvia Scott Thomas Jackson
-
Protara Therapeutics Inc. Same sectorvia Cynthia Smith
-
Tvardi Therapeutics Inc. Same sectorvia Cynthia Smith
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $499,087
- 9 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 9, 2026 | Esther Rajavelu Director, Officer (See Remarks) | Open-market sale | −40,851 | $1.04 | $42,485 |
| Aug 3, 2026 | Zack Debra Officer (Chief Medical Officer) | Grant or award | +162,311 | — | — |
| Jun 23, 2026 | Milind Deshpande Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Kathleen Tregoning Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Cynthia Smith Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Patrick V.j.j. Vink Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Frank E. Thomas Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Scott Thomas Jackson Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | John C. Pottage Jr. Director | Grant or award | +10,000 | — | — |
| May 4, 2026 | Rajavelu Esther Officer (See Remarks) | Open-market sale | −25,240 | $2.51 | $63,352 |
| Feb 6, 2026 | Rajavelu Esther Officer (See Remarks) | Open-market sale | −37,101 | $2.36 | $87,558 |
| Feb 6, 2026 | Keutzer Timothy Officer (Chief Operating Officer) | Open-market sale | −18,652 | $2.36 | $44,019 |
| Feb 6, 2026 | Rajavelu Esther Officer (See Remarks) | Open-market sale | −50,816 | $2.36 | $119,926 |
| Feb 4, 2026 | Keutzer Timothy Officer (Chief Operating Officer) | Open-market sale | −3,471 | $2.24 | $7,775 |
| Feb 3, 2026 | Keutzer Timothy Officer (Chief Operating Officer) | Open-market sale | −24,224 | $2.14 | $51,839 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Spero Therapeutics Inc.
Who is the CEO of Spero Therapeutics Inc.?
Ankit Mahadevia is Spero Therapeutics Inc.'s CEO and President.
How many directors are on Spero Therapeutics Inc.'s board?
Spero Therapeutics Inc.'s board has 11 directors: Ankit Mahadevia, Cynthia Smith, Esther Rajavelu, Frank E. Thomas, John C. Pottage Jr., Kathleen Tregoning, Milind Deshpande, Patrick V.j.j. Vink, Sath Shukla, Scott Thomas Jackson and 1 other.
Are Spero Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Spero Therapeutics Inc. insiders made no open-market purchases and sold $499,087 of shares in 9 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="spero-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.